Retatrutide Phase 2: 48-Week Trial Data Explained
A clinic operator running weekly injectable programs gets the same question from three different patients in one afternoon: "What about the one that's supposedly stronger than tirzepatide?" That…
Latest Article
Read More →
Compounded Semaglutide Legal Status by Channel
A medical spa running forty semaglutide patients a week out of a strip-mall suite in Scottsdale got a call from its 503B supplier in March 2025: bulk semaglutide vials were being discontinued…
Clinical Trials
View all 18 →Trial readouts, endpoints, and what the data does — and does not — establish.
GLP-3 Trial Design: Statistical Power in Small Studies
A contract research site running its first peptide-obesity study enrolls 22 subjects, splits them 11 and 11, runs the protocol for 16 weeks, and gets a p-value of 0.11 on the primary endpoint. The…
GLP-1 Trial Design: Single-Arm vs Double-Blind Protocols
A research team registering a 12-week open-label study of a novel GLP-1 peptide candidate through a contract research organization can move from protocol concept to first-patient-dosed in under…
Informed Consent in GLP-1 and GLP-3 Clinical Trials: Patient Selection and Data Integrity Standards
A site coordinator is screening a 52-year-old candidate for a Phase 3 multi-receptor agonist trial. BMI is 29.6 — just under the protocol's 30 kg/m2 threshold. Fasting glucose is borderline…
Identifying Inclusion Criteria for GLP-3 Clinical Trials: A Guide to Study Design and Enrollment Strategy
A site coordinator running a phase 2 metabolic trial pulls the enrollment tracker on a Friday afternoon: 260 candidates pre-screened over eight weeks, 91 consented to formal screening, and only 54…
Designing Effective Clinical Trial Protocols for GLP-3 Peptide Therapy: Key Considerations for Efficacy and Safety
A mid-size CRO running a Phase 2 obesity trial for a triple-receptor peptide submitted its protocol to the FDA with a four-week dose-titration schedule compressed from the sponsor's original…
Comparisons
View all 17 →Head-to-head pharmacology: efficacy, dosing, tolerability, and approval status.
CagriSema vs Tirzepatide: What REDEFINE Trials Show
A clinic intake coordinator fields the same question three times in one afternoon: a patient has read a press release about a new obesity drug that beat tirzepatide, and wants to know if it's worth…
GLP-3 vs GLP-1: Comparing Peptide Therapy Outcomes
A patient forwards a supplier's product page advertising a "GLP-3 peptide protocol" and asks a straightforward question: is this the successor to semaglutide, and does the research back it up? The…
GLP-1 vs GLP-3 Analogues: Efficacy and Safety Data
GLP-1 vs GLP-3: Clarifying the Terminology Before Comparing Outcomes A patient walks into a medical weight-loss clinic holding up a phone screen and asks to be switched from semaglutide to "the new…
GLP-1 Receptor Agonists vs Glucagon Receptor Antagonists for Obesity: What the Trial Data Actually Shows
Two Levers on the Same Metabolic CircuitA metabolic clinic that has run weight-management protocols for a few years eventually gets the question from a patient who has been reading peptide forums…
GLP-3 Peptide Therapy and Metabolic Syndrome: A Comparative Analysis of GLP-1, Dual, and Triple Agonist Trial Data
A clinician fielding a patient's question about "GLP-3 peptide therapy" for metabolic syndrome will not find a corresponding entry in PubMed, ClinicalTrials.gov, or any major endocrinology…
GLP-1 vs. GLP-3 Mimetic Peptides for Weight Loss: A Systematic Comparison of Clinical Trial Outcomes
A clinic operator running a medical weight-management program gets the same question every week from patients who have read about newer peptides online: "Should I wait for the GLP-3 drug instead of…
Mechanism
View all 22 →Receptor biology and pharmacokinetics behind the incretin class.
Orforglipron: Oral Non-Peptide GLP-1 vs Injectables
A clinician reviewing a patient's chart notes something specific: needle aversion documented three visits in a row, an A1c that hasn't moved, and a patient who has asked twice whether there's "a…
GLP-3 and GRP2: Anorexigenic Signaling Explained
When a Plateau Isn't About GLP-1 AnymoreA research coordinator running a metabolic-health intake desk fields a version of this question two or three times a month: a patient stalled on semaglutide…
GLP-1 Receptor Variability in Obesity Treatment
Same Dose, Different Outcome: A Pattern Clinics Keep SeeingA metabolic clinic running a 240-patient semaglutide titration cohort will, sooner or later, produce a chart that does not make intuitive…
GLP-1 vs. GLP-3 Receptor Mechanisms: What Actually Differs at the Cellular Level
When a Patient Asks About "GLP-3"A clinician fielding intake questions ahead of a GLP-1 prescription hears it more often now: "Is GLP-3 stronger than GLP-1?" or "I saw a research peptide site…
GLP-3 Receptor Binding Kinetics and Obesity Treatment: What the Pharmacology Data Actually Shows
A research team evaluating vendor claims about "GLP-3 receptor binding optimization" for an obesity-focused peptide will not find that receptor described anywhere in the structural biology…
Unraveling GLP-3 Receptor Signaling: What the Evidence Shows About Insulin Sensitivity and Glucose Homeostasis
Search interest in "GLP-3 receptor" signaling has climbed alongside the popularity of next-generation incretin peptides, but the term does not correspond to any distinct hormone or receptor…
Compounds & Peptides
View all 15 →Compound-level profiles across the research-peptide landscape.
Mazdutide Phase 3 Trial Data Explained
A research team scanning ClinicalTrials.gov for next-generation obesity compounds in 2023 would have found something unusual: a Phase 3 program for a GLP-1/glucagon dual agonist running entirely at…
Survodutide Phase 2: Liver Fat and Weight Loss Data
Survodutide: A Dual GLP-1/Glucagon Receptor Agonist A patient on a stable GLP-1 regimen for eighteen months hits a weight-loss plateau and a liver panel that still shows elevated ALT despite steady…
GLP-3 Receptor Binding Agents: What the Research Shows
When the Front Desk Starts Fielding "GLP-3" Calls A clinic running a research-support line for peptide patients started logging a new pattern in its call notes last quarter: callers asking…
GLP-1 Peptide Reconstitution and Stability Guide
Why Peptide Stability Determines Research Outcomes A compounding pharmacy processing roughly 300 reconstituted GLP-1 receptor agonist vials a month ran a routine potency check on stock that had…
Optimizing GLP-1 Peptide Sequences for Enhanced Efficacy in Weight-Loss Therapeutics: A Research Review
A compounding pharmacy client once sent over three vials of the same nominal peptide, sourced from three different suppliers, and asked why one batch showed visibly reduced potency in downstream…
Optimizing GLP-3 Peptide Stability for Effective Research: A Guide to Formulation and Handling Techniques
A contract research lab tracking a multi-week in-vitro binding assay lost an $18,000 reference-standard batch of a GLP-1 analog because a supplier shipment sat at ambient temperature for 36 hours…
Lab Handling & Reconstitution
Topic page →Reconstitution, storage, and handling for laboratory research.
Reconstituting Lyophilized Peptides: Ratios & Storage
A research lab logs a batch of results that don't match the prior month's run under an identical protocol. The peptide vial looks the same, the dose calculation checks out on paper, and the…
Standard Operating Procedures for GLP-3 Peptide Reconstitution in Clinical Settings
When a Reconstitution Error Becomes a Documented Deviation A research coordinator at a mid-sized peptide research facility reconstituted a lyophilized vial labeled for 5 mg net peptide content with…
Sterile Filtration Techniques for Reconstituted Peptide Solutions: A Lab Protocol Guide
A research team conducting in vitro GLP-1 receptor (GLP-1R) binding assays observes receptor activation values 40–60% below published EC50 benchmarks across three consecutive experiments using a…
Bacteriostatic Water vs Sterile Water for Peptide Reconstitution
Reconstitution diluent selection is one of the more consequential — and most under-documented — decisions in peptide research. The two diluents in widest use, bacteriostatic water for injection…
Safety & Side Effects
View all 9 →Adverse-event data, contraindications, and tolerability signals.
Gastroparesis & GLP-1 Agonists: Incidence, Risk, When to Stop
A 54-year-old patient with type 2 diabetes of 11 years' duration starts tirzepatide for weight management. By week 14, at the 10 mg maintenance dose, she reports bloating, early fullness after a…
Compounded Semaglutide vs FDA-Approved Brands: Stability and Sterility Considerations
A Formulation Problem That Reached the Emergency Department A patient presents with an injection-site abscess three weeks into a subcutaneous semaglutide protocol sourced from a state-licensed…
Long-Term Tirzepatide Maintenance Dosing: SURMOUNT-4 Withdrawal and Regain Findings
The scenario presents itself with increasing frequency in obesity medicine practice: a patient who has completed 36 weeks of tirzepatide (Mounjaro/Zepbound) titration, achieved 10 mg or 15 mg/week…
Tirzepatide and Sleep Apnea: What the SURMOUNT-OSA Trial Data Shows
A patient presents with severe obstructive sleep apnea — apnea-hypopnea index (AHI) of 64 events per hour — and a BMI of 39 kg/m². Two CPAP trials have failed: one due to claustrophobia, one due to…
GLP-1 Therapy and Lean Muscle Mass: Preserving Tissue During Rapid Weight Loss
GLP-1 therapy and lean muscle mass preservation represent one of the most clinically consequential body composition questions in pharmacological weight management. A patient on semaglutide 2.4 mg…
Semaglutide Dose Titration Schedules: Evidence-Based Protocols from Pivotal Trials
A patient with a BMI of 38 initiates semaglutide 0.25 mg/week (Wegovy) and advances on calendar schedule at week 4 to 0.5 mg. Nausea begins on day 2 of the new dose. At week 8, the prescriber…
Policy & Access
Topic page →Regulatory status, shortages, compounding, and the access landscape.
Compounded Semaglutide Legal Status by Channel
A medical spa running forty semaglutide patients a week out of a strip-mall suite in Scottsdale got a call from its 503B supplier in March 2025: bulk semaglutide vials were being discontinued…
Compounded Semaglutide Pharmacy Access During the 2025 FDA Shortage Transition
The Shortage Is Over — But the Access Problem Isn't In February 2025, the FDA officially removed semaglutide from its drug shortage database. On paper, that sounds like a win. In practice…
Foundations
Topic page →Plain-language starting points for the GLP-1 / GLP-3 landscape.
Evidence-Based Guide to GLP-1 & GLP-3 Therapies
Clinical evidence and mechanism of action for GLP-1 and GLP-3 weight-loss therapies, sourced from peer-reviewed trials and medical literature.
What Is GLP3 Weight Loss?
An introduction to GLP3 Weight Loss as an independent educational resource and research-product catalog — what we are, what we are not, and how we connect readers with independent licensed providers.
GLP Weight Loss Guide
A practical, evidence-based primer on GLP-1 weight-loss therapy — how the peptides are studied, expected results in trials, and how the research is read.
GLP3 Weight Loss Overview
How GLP3 Weight Loss works as an independent information and research-product resource — our evidence-first approach and our referral model to independent licensed providers.